Insider Transactions in Q2 2024 at Mereo Biopharma Group PLC (MREO)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 26
2024
|
Alexandra Hughes Wilson |
SELL
Open market or private sale
|
Direct |
22,968
-39.93%
|
$68,904
$3.39 P/Share
|
|
Jun 26
2024
|
Denise Scots Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
92,273
-11.51%
|
$276,819
$3.39 P/Share
|
|
Jun 26
2024
|
Christine Ann Fox Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
29,439
-33.83%
|
$88,317
$3.39 P/Share
|
|
Jun 26
2024
|
John A. Lewicki Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
16,808
-25.63%
|
$50,424
$3.39 P/Share
|
|
Jun 26
2024
|
Charles Sermon General Counsel |
SELL
Open market or private sale
|
Direct |
32,187
-14.86%
|
$96,561
$3.39 P/Share
|
|
Jun 25
2024
|
Alexandra Hughes Wilson |
SELL
Open market or private sale
|
Direct |
10,134
-14.98%
|
$30,402
$3.69 P/Share
|
|
Jun 25
2024
|
Denise Scots Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,712
-4.83%
|
$122,136
$3.69 P/Share
|
|
Jun 25
2024
|
Christine Ann Fox Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,990
-12.99%
|
$38,970
$3.69 P/Share
|
|
Jun 25
2024
|
John A. Lewicki Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,416
-10.16%
|
$22,248
$3.69 P/Share
|
|
Jun 25
2024
|
Charles Sermon General Counsel |
SELL
Open market or private sale
|
Direct |
14,202
-6.15%
|
$42,606
$3.69 P/Share
|
|
Jun 21
2024
|
John A. Lewicki Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
69,000
+48.59%
|
-
|
|
Jun 21
2024
|
Denise Scots Knight Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
282,090
+25.08%
|
-
|
|
Jun 21
2024
|
Alexandra Hughes Wilson |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+47.0%
|
-
|
|
Jun 21
2024
|
Christine Ann Fox Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
90,000
+47.37%
|
-
|
|
Jun 21
2024
|
Charles Sermon General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
98,400
+29.89%
|
-
|
|
Jun 17
2024
|
Jeremy Bender |
BUY
Grant, award, or other acquisition
|
Indirect |
12,550
+50.0%
|
$37,650
$3.99 P/Share
|
|
Jun 17
2024
|
Michael S Wyzga |
BUY
Grant, award, or other acquisition
|
Direct |
25,050
+50.0%
|
$75,150
$3.99 P/Share
|
|
May 22
2024
|
Alexandra Hughes Wilson |
SELL
Payment of exercise price or tax liability
|
Direct |
67,901
-80.7%
|
$67,901
$1.21 P/Share
|
|
May 22
2024
|
Alexandra Hughes Wilson |
SELL
Open market or private sale
|
Direct |
100,432
-53.4%
|
$200,864
$2.97 P/Share
|
|
May 22
2024
|
Alexandra Hughes Wilson |
BUY
Exercise of conversion of derivative security
|
Direct |
168,333
+47.8%
|
$168,333
$1.21 P/Share
|